FTK · Flotek Industries, Inc.

Current Thesis

Flotek Industries’ recovery case rests on chemistry growth and analytics earnings; confirmation at Q3 2026 results would support it, while a weekly close below $23.93, the 2026-08-28 reference close, would invalidate it.

The material change since August is the 2026-09-09 increase in annual guidance, which management attributed to international chemistry demand. As an inference, the narrative is accelerating — that new operating headline and Benzinga’s 2026-09-09 gainers coverage mark renewed attention. A loss of the August reference close would contradict that recovery interpretation. Flotek’s September 9 release.

The Puerto Rico power-contract thesis remains broken: Flotek’s Form 8-K filed 2026-08-19 reported termination effective 2026-08-18. The chemistry-led recovery is a separate case; the guidance increase does not establish a replacement power customer.

Bullish and bearish views on Flotek Industries, Inc.

The model's bull view on Flotek Industries, Inc. (FTK), in brief: The operating outlook increased again. On 2026-09-09, management raised FY2026 revenue guidance to $360–370 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to $50–54 million. These are company forecasts, not reported results. Company… The bear view: The power award remains terminated. The 2026-08-19 Form 8-K said the Puerto Rico Electric Power Authority contract generated no revenue or payments and equipment deployment had not begun. The approximately $400 million of expected ten-year backlog announced on 2026-08-03 cannot… Both cases follow in full.

Bull Case

• The operating outlook increased again. On 2026-09-09, management raised FY2026 revenue guidance to $360–370 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to $50–54 million. These are company forecasts, not reported results. Company release.

• Analytics already contributes reported profit. Q2 2026 Data Analytics revenue was $19.2 million and the segment supplied 51% of gross profit, according to the 2026-08-04 results. That establishes an operating contribution beyond the terminated power award, although one quarter cannot establish its persistence. Q2 earnings release.

• International demand supplies another test. On 2026-09-09, management said second-half 2026 international chemistry sales could exceed $40 million, supported by Saudi Arabian activity. Reported sales at or below that amount would fail to confirm this component of management’s outlook. Company release.

Bear Case

• The power award remains terminated. The 2026-08-19 Form 8-K said the Puerto Rico Electric Power Authority contract generated no revenue or payments and equipment deployment had not begun. The approximately $400 million of expected ten-year backlog announced on 2026-08-03 cannot support the current case after termination.

• Analytics durability remains unproved. The $19.2 million of Q2 2026 segment revenue included $7.1 million of related-party revenue associated with ProFrac, according to the quarterly disclosures cited in the August coverage. A Q3 decline below that segment revenue benchmark would weaken the profit-mix argument; the available sample is too small to establish durable independence from related-party demand.

• Disclosure issues remain distinct risks. The 2026-08-19 Form 8-K reported that Puerto Rico’s Oversight Board referred contract issues to law-enforcement authorities. That disclosure establishes a referral, not a finding of wrongdoing by Flotek; a subsequent filing naming the company in a formal inquiry would materially worsen the case.

Setup & Price Structure

The adjusted daily series records a 2026-09-11 close of $27.33, a three-month price increase of 10.9%, and a 14-day relative strength index (RSI) of 63.8. The shares were 29.6% below the series’ 52-week high of $38.82 on that date. Those measurements show positive recent momentum alongside substantial unrecovered ground.

The earlier thesis’s weekly-close threshold of $28 has already been breached by the 2026-09-11 weekly close. It cannot remain an untriggered condition. For the new operating-recovery case, $23.93 is the explicitly dated 2026-08-28 reference close; the available observations do not establish it as a repeatedly tested support shelf.

Benzinga carried both the guidance headline and a gainers roundup mentioning Flotek on 2026-09-09. That is observable coverage clustering, but the sample is too small to support a retail-crowding claim. Current moving-average distances, ownership flows and short-interest measurements are missing, so none establishes expanding participation or a squeeze.

Catalyst Calendar (next 30 days)

• 2026-09-24 — NYSE Investor Access, Energy & Utilities. Flotek’s investor-relations homepage, checked 2026-09-13, lists virtual investor meetings on this date. The listing establishes an attention event; it does not promise new results or guidance. Company event listing.

• ~2026-11-03, estimated — Q3 2026 results. This later event is the operating test the thesis turns on. MarketBeat estimates the date; a company-confirmed release date is unavailable. Confirmation requires retention of the September guidance and Data Analytics revenue at least matching its Q2 2026 level. Earnings-date estimate.

What Would Change Our Mind

Losing the recovery above the 2026-08-28 reference close would break the price thesis: a weekly close below $23.93 is the observable condition. The prior $28 condition remains a recorded failure of the earlier case.

Operating confirmation requires Q3 2026 Data Analytics revenue of at least $19.2 million and retention of the 2026-09-09 annual outlook. A revenue-guidance reduction below $360 million or adjusted EBITDA guidance below $50 million would break the fundamental case independently of price.

Correlation Notes

This is a single-name setup, with no established theme-cluster support. Q2 2026 related-party analytics revenue of $7.1 million links part of the operating exposure to ProFrac, while management’s 2026-09-09 explanation links the latest guidance increase to international chemistry. Those are business exposures, not measured stock-return correlations. No paired return series is available to substantiate a correlation with oil prices, energy-service equities or artificial-intelligence infrastructure stocks.